Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) has been granted exclusive global rights to commercialise patented MicroMAX microencapsulation technology for the treatment of animals using plant-derived compounds from hemp and cannabis.
CannPal Managing Director, Layton Mills, said the agreement with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) for use in the field of Animal Therapeutics, follows 18 months of evaluation.
CannPal has also announced that it has confirmed significant anti-inflammatory activity in the hemp-derived oil formulation used during the evaluation of MicroMAX.
“After 18 months of due diligence, I’m delighted to announce that we’ve been granted the exclusive rights to CSIRO’s patented MicroMAX technology platform for use in the animal health market. It’s a highly effective technology with unmatched stability and protection capabilities, enabling us to deliver hemp and cannabis compounds to pets in a new and innovative way,” Mr Mills said.
“Additionally, it’s exciting to see significant anti-inflammatory activity in the hemp-derived formulation used during the evaluation. This gives us confidence to explore the ways in which we can commercialise complementary products for the animal health market with high quality evidence- based formulations using some of the less regulated compounds in the hemp plant, to support CannPals ongoing pharmaceutical development which remains our core focus.”
MicroMAX is CSIRO’s patented microencapsulation technology platform designed to encapsulate microscopic droplets of oil in a special food grade material, to protect bioactive ingredients from oxidation and help deliver them to the gastrointestinal (GI) tract.
Microencapsulation is a process widely used in food and drug manufacturing that protects the integrity of functional ingredients and helps maintain the nutritional value, shelf-life and flavour of the finished product, while enhancing the delivery of the active compounds.
CannPal has been evaluating the Technology with CSRIO to develop new and innovative product formats using less regulated compounds from the hemp plant, as part of the company’s near-term revenue generation strategy to support its ongoing pharmaceutical research and development.
The 18-month evaluation demonstrated that MicroMAX can successfully encapsulate CannPals oil formulations with superior protection capabilities and substantial improvement in oxidative stability, enabling CannPal to add hemp and cannabis oils to a wider range of innovative new product applications for companion animals.
The licence provides CannPal with the exclusive global rights to apply the Technology to proprietary oil formulations for the development and commercialisation of novel animal health products, using plant-derived compounds from hemp and cannabis.
